BR Biopharma (BRBI) vs. The Competition Head-To-Head Review

BR Biopharma (NASDAQ:BRBI) is one of 1,747 public companies in the “Capital Markets” industry, but how does it contrast to its competitors? We will compare BR Biopharma to similar companies based on the strength of its earnings, valuation, profitability, risk, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares BR Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
BR Biopharma Competitors	267.78%	78.34%	3.56%

Analyst Recommendations

This is a summary of current recommendations and price targets for BR Biopharma and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	0	0	0	1.00
BR Biopharma Competitors	5333	19669	21876	610	2.37

As a group, “Capital Markets” companies have a potential upside of 21.94%. Given BR Biopharma’s competitors stronger consensus rating and higher possible upside, analysts clearly believe BR Biopharma has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

30.6% of shares of all “Capital Markets” companies are owned by institutional investors. 29.4% of BR Biopharma shares are owned by insiders. Comparatively, 13.0% of shares of all “Capital Markets” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.1% and pay out 28.0% of their earnings in the form of a dividend.

Earnings & Valuation

This table compares BR Biopharma and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BR Biopharma	$2.23 billion	$31.36 million	136.57
BR Biopharma Competitors	$5.14 billion	$397.44 million	10.73

BR Biopharma’s competitors have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

BR Biopharma competitors beat BR Biopharma on 11 of the 14 factors compared.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.